7 completed, 3 not yet recruiting, 3 recruiting, 1 unknown. 6 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 4 | Recruiting 3, Not yet recruiting 1 |
Follow Wuhan Createrna Science and Technology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 40 | 2025-12-01 | 2025-07-29 |
| Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) MY008211A tablets, MY008211A tablets matched placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 72 | 2024-12-31 | 2024-11-18 |
| QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension QR12000 75mg, QR12000 75mg placebo, QR12000 150mg - Essential Hypertension | Phase 3 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 810 | 2024-12-30 | 2024-12-06 |
| Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 / Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 120 | 2024-11-30 | 2025-04-18 |
| A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function MY008211A tablets - Hepatic Insufficiency (MeSH ID: D048550) | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 24 | 2024-09-20 | 2026-06-04 |
| Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 20 | 2024-08-30 | 2025-05-09 |
| Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy MY008211A tablets, Eculizumab Injection - Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 3 | Recruiting | Wuhan Createrna Science and Technology Co., Ltd | 66 | 2024-08-30 | 2025-05-09 |
| To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects MY008211A tablets, Placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Unknown | Wuhan Createrna Science and Technology Co., Ltd | 16 | 2024-08-10 | 2024-08-09 |
| A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 34 | 2023-07-06 | 2025-07-30 |
| QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study QR052107B 100 mg, QR052107B 400 mg, Placebo - Cough | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 270 | 2023-06-21 | 2025-04-10 |
| A Study of Multiple Ascending Doses MY008211A in Healthy Adults MY008211A tablets, MY008211A tablets matched placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 40 | 2023-01-10 | 2023-09-08 |
| A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 75 mg placebo, QR12000 Compound Tablets 150 mg - Essential Hypertension | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 391 | 2022-12-29 | 2026-07-14 |
| Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 12 | 2022-09-26 | 2023-04-25 |
| A Study of Single-dose MY008211A in Healthy Adults MY008211A tablets, Placebo - Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 63 | 2022-05-27 | 2023-09-08 |
Hemoglobinuria, Paroxysmal (9) · Essential Hypertension (2) · Cough (1) · Glomerulonephritis, IGA (1) · Hepatic Insufficiency (1) · Kidney Diseases (1)
Valsartan (2) · sacubitril (2) · eculizumab (1)
China (13)
Fengkui Zhang, Ph.D (1) · Haiyan Li, PhD (1) · Hong Zhang, PH.D. (1) · Ting Yang, MD (1) · YaNan Wang, PHD (1)